- Home
- BANC vs AKRO Comparison
BANC vs AKRO Comparison
Compare BANC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANC
- AKRO
- Stock Information
- Founded
- BANC 1941
- AKRO 2017
- Country
- BANC United States
- AKRO United States
- Employees
- BANC N/A
- AKRO N/A
- Industry
- BANC Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BANC Finance
- AKRO Health Care
- Exchange
- BANC Nasdaq
- AKRO Nasdaq
- Market Cap
- BANC 2.2B
- AKRO 3.9B
- IPO Year
- BANC N/A
- AKRO 2019
- Fundamental
- Price
- BANC $14.32
- AKRO $51.41
- Analyst Decision
- BANC Buy
- AKRO Strong Buy
- Analyst Count
- BANC 11
- AKRO 6
- Target Price
- BANC $17.09
- AKRO $82.50
- AVG Volume (30 Days)
- BANC 2.1M
- AKRO 1.8M
- Earning Date
- BANC 07-22-2025
- AKRO 08-08-2025
- Dividend Yield
- BANC 2.80%
- AKRO N/A
- EPS Growth
- BANC N/A
- AKRO N/A
- EPS
- BANC 0.65
- AKRO N/A
- Revenue
- BANC $964,190,000.00
- AKRO N/A
- Revenue This Year
- BANC $8.39
- AKRO N/A
- Revenue Next Year
- BANC $10.47
- AKRO N/A
- P/E Ratio
- BANC $21.97
- AKRO N/A
- Revenue Growth
- BANC 415.34
- AKRO N/A
- 52 Week Low
- BANC $11.52
- AKRO $21.02
- 52 Week High
- BANC $18.08
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- BANC 59.94
- AKRO 47.91
- Support Level
- BANC $13.78
- AKRO $53.05
- Resistance Level
- BANC $14.25
- AKRO $57.35
- Average True Range (ATR)
- BANC 0.33
- AKRO 2.45
- MACD
- BANC 0.05
- AKRO -0.64
- Stochastic Oscillator
- BANC 73.38
- AKRO 4.65
About BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.